Cardiovascular Risk of Resistant Hypertension: Dependence on Treatment-Time Regimen of Blood Pressure-Lowering Medications

被引:73
|
作者
Ayala, Diana E. [1 ]
Hermida, Ramon C. [1 ]
Mojon, Artemio [1 ]
Fernandez, Jose R. [1 ]
机构
[1] Univ Vigo, Bioengn & Chronobiol Labs, Vigo 36310, Pontevedra, Spain
关键词
Ambulatory blood pressure monitoring; Cardiovascular risk; Chronotherapy; Resistant hypertension; Sleep-time blood pressure; CONVERTING-ENZYME-INHIBITOR; PROGNOSTIC VALUE; THERAPEUTIC TARGET; CIRCADIAN-RHYTHMS; DOUBLE-BLIND; CHRONOTHERAPY; DIAGNOSIS; EVENTS; PATTERN; MORTALITY;
D O I
10.3109/07420528.2012.701455
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In resistant hypertension, ingesting one or more blood pressure (BP)-lowering medications at bedtime is associated with significant reduction of sleep-time BP, a sensitive prognostic marker of cardiovascular disease (CVD) risk. This randomized trial investigated if bedtime therapy with at least one hypertension medication exerts better BP control and CVD risk reduction than conventional, morning-time therapy with all medications. We conducted a prospective, open-label, blinded-endpoint trial on 776 patients (387 men/389 women) with resistant hypertension, 61.6 +/- 11.2 (mean +/- SD) yrs of age. Patients were randomized to ingest all their prescribed hypertension medications upon awakening or >= 1 of them at bedtime. BP was measured by ambulatory monitoring for 48 h at baseline, and again annually or more frequently (quarterly) if treatment adjustment was required. After a median follow-up of 5.4 yrs (range, .5-8.5 yrs), participants ingesting >= 1 hypertension medications at bedtime showed a significantly lower hazard ratio (HR) of total CVD events (adjusted by age, sex, and diabetes) than those ingesting all medications upon awakening (.38 [95% CI: .27-.55]; number of events 102 vs. 41; p<.001). The difference between groups in the adjusted HR of major CVD events (a composite of CVD death, myocardial infarction, ischemic stroke, and hemorrhagic stroke) was also statistically significant (.35 [95% CI: .18-.68]; number of events 32 vs. 12; p=.002). At the last evaluation, patients treated with the bedtime versus awakening-time-treatment regimen showed significantly lower sleep-time systolic/diastolic BP mean values (121.6/65.4 vs. 113.0/61.1 mm Hg; p<.001) and higher prevalence of controlled ambulatory BP (61% vs. 46%; p<.001). The progressive decrease in the sleep-time systolic BP mean during follow-up was the most significant predictor of event-free survival (15% risk reduction per 5 mm Hg decreased asleep systolic BP mean). Among patients with resistant hypertension, ingestion of at least one hypertension medication at bedtime, compared with all medications upon waking, resulted in improved ambulatory BP control and fewer hard and soft CVD events. (Author correspondence: rhermida@uvigo.es)
引用
收藏
页码:340 / 352
页数:13
相关论文
共 50 条
  • [21] Blood pressure-lowering efficacy of loop diuretics for primary hypertension
    Musini, Vijaya M.
    Rezapour, Pouria
    Wright, James M.
    Bassett, Ken
    Jauca, Ciprian D.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (05):
  • [22] Secondary prevention of stroke by blood pressure-lowering treatment
    Hisatomi Arima
    John Chalmers
    Current Hypertension Reports, 2006, 8 : 317 - 323
  • [24] Secondary prevention of stroke by blood pressure-lowering treatment
    Arima, Hisatomi
    Chalmers, John
    CURRENT HYPERTENSION REPORTS, 2006, 8 (04) : 317 - 323
  • [25] BLOOD PRESSURE-LOWERING, ANTIHYPERTENSIVE TREATMENT AND INCIDENT DIABETES
    Nazarzadeh, Milad
    Bidel, Zeinab
    Canoy, Dexter
    Copland, Emma
    Wamil, Malgorzata
    Byrne, Karl Smith
    Sundstrom, Johan
    Teo, Koon
    Davis, Barry R.
    Chalmers, John
    Pepine, Carl J.
    Dehghan, Abbas
    Bennet, Derrick A.
    Smith, George Davey
    Rahimi, Kazem
    JOURNAL OF HYPERTENSION, 2021, 39 : E8 - E9
  • [26] Vasodilators, Blood Pressure-Lowering Medications, and Age-Related Macular Degeneration
    Klein, Ronald
    Klein, Barbara E. K.
    OPHTHALMOLOGY, 2014, 121 (08) : 1604 - 1611
  • [27] The case for absolute cardiovascular risk-based blood pressure-lowering treatment decisions: data from the SPRINT trial
    Sundstrom, Johan
    Karmali, Kunal N.
    JOURNAL OF HUMAN HYPERTENSION, 2020, 34 (07) : 544 - 545
  • [28] The case for absolute cardiovascular risk-based blood pressure-lowering treatment decisions: data from the SPRINT trial
    Johan Sundström
    Kunal N. Karmali
    Journal of Human Hypertension, 2020, 34 : 544 - 545
  • [29] Sustained blood pressure lowering in resistant hypertension
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (10) : 551 - 551
  • [30] Blood pressure lowering and cardiovascular risk
    Stoner, Lee
    Wu, Brian
    LANCET, 2014, 384 (9956): : 1746 - 1746